Interestingly, Buda et al. [46] retrospectively evaluated the role of MRP1 and MDR1 on outcomes in relapsed and/or refractory MM patients in therapy with bortezomib and pegylated doxorubicin. Here, ABCB1 is linked to Miyoshi myopathy.